Adaptimmune Therapeutics PLC 8-K filings
Adaptimmune Therapeutics successfully held its annual general meeting, re-electing all nominated directors and approving all proposed resolutions.
8-K: Adaptimmune and Genentech Strategic Collaboration Terminated, Company Focuses on Afami-cel Launch
Adaptimmune Therapeutics' strategic collaboration with Genentech has been terminated, and the company is now focusing on launching afami-cel and developing its sarcoma franchise.
Adaptimmune reports positive financial results for 2023, highlighted by the FDA's acceptance of the BLA for afami-cel with priority review and a PDUFA date of August 4, 2024.
Adaptimmune Therapeutics has reappointed Cintia Piccina as Chief Commercial Officer, effective March 18, 2024, to lead the commercialization efforts for their late-stage cancer therapies.
Adaptimmune Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Global Select Market.
The FDA has accepted Adaptimmune's Biologics License Application for afami-cel, a novel T-cell therapy for advanced synovial sarcoma, with a priority review and a target action date of August 4, 2024.